ormulation technology for stabilized lipid-based nanoparticles (LNPs)

This was largely made possible by major advances in the formulation technology for stabilized lipid-based nanoparticles (LNPs). Design of the cationic ionizable lipids, which are a key component of the LNP formulations, with an acid dissociation constant (pKa) close to the early endosomal pH, would not only ensure effective encapsulation of mRNA into the stabilized lipoplexes within the LNPs, but also its subsequent endosomal release into the cytoplasm after endocytosis.
Unlike other gene therapy modalities, which require nuclear delivery, the site of action for exogenous mRNA vaccines is the cytosol where they get translated into antigenic proteins and thereby elicit an immune response. LNPs also protect the mRNA against enzymatic degradation by the omnipresent ribonucleases (RNases). Cationic nano emulsion (CNE) is also explored as an alternative and relatively thermostable mRNA vaccine delivery vehicle.
In this review, we have summarized the various delivery strategies explored for more details joplink Recombinant Human Serine  mRNA vaccines, including naked mRNA injection; ex vivo loading of dendritic cells; CNE; cationic peptides; cationic polymers, and finally the clinically successful COVID-19 LNP vaccines  (Pfizer/BioNTech and Moderna vaccines)-their components, design principles, formulation parameter optimization, and stabilization challenges. Despite the clinical success of LNP-mRNA vaccine formulations, there is a specific need to enhance their storage stability above 0 °C for these lifesaving vaccines to reach the developing.

Understanding the role of microperimetry in glaucoma

The present narrative review attempts to provide an overview on the use of microperimetry or fundus-driven perimetry in glaucoma, considering the clinical use, the different strategies and limits compared to standard automated perimetry.
 An electronic database (PubMed and Medline) search was performed of articles of any type published in the English language between 1998 and 2020 with a combination of the following terms: microperimetry, glaucoma, primary open-angle chronic glaucoma, visual field, Humphrey visual field, fundus automated perimetry.
All the original articles, case reports, and short series analyzed were included in the present review, offering an excursus on the strengths and limitations characterizing the use of microperimetry in glaucomatous patients. The characteristics of a recently introduced fundus-driven perimetry Compass (CMP; Centervue, Padua, Italy) were also included.
Although there remain several contradictions regarding routine use of microperimetry and the restricted research on this topic limits our ability to draw firm conclusions, microperimetry may be preferable in cases of localized retinal nerve fiber layer defects in patients with primary open-angle glaucoma and normal visual field. However, standard automated perimetry remains the gold standard for monitoring glaucoma, especially in patients with diffuse retinal nerve fiber layer impairment and visual field defects. The newly introduced Compass device can potentially provide a more accurate structural-functional evaluation than standard automated perimetry and can therefore produce superior testing reliability.

Ligand-Directed GPCR Antibody Discovery

Developing affinity reagents recognizing and modulating G-protein coupled receptors (GPCR) function by traditional animal immunization or in vitro screening methods is challenging. Some anti-GPCR antibodies exist on the market, but the success rate of development is still poor compared with antibodies targeting soluble or peripherally anchored proteins.

  • More importantly, most of these antibodies do not modulate GPCR function. The current pipeline for antibody development primarily screens for overall affinity rather than functional epitope recognition. We developed a new strategy utilizing natural ligand affinity to generate a library of antibody variants with an inherent bias toward the active site of the GPCR.
  • Instead of using phage libraries displaying antibodies with random CDR sequences at polymorphism sites observed in natural immune repertoire sequences, we generated focused antibody libraries with a natural ligand encoded within or conjugated to one of the CDRs or the N-terminus.
  • To tailor antibody binding to the active site, we limited the sequence randomization of the antibody in regions holstering the ligand while leaving the ligand-carrying part unaltered in the first round of randomization. With hits from the successful first round, the second round of randomization of the ligand-carrying part was then performed to eliminate the bias of the ligand.
  • Based on our results on three different GPCR targets, the proposed pipeline will enable the rapid generation of functional antibodies (both agonists and antagonists) against high-value targets with poor function epitope exposures including GPCR, channels, transporters as well as cell surface targets whose binding site is heavily masked by glycosylation.

endohedral trihedral metallo-borospherenes with spherical aromaticity

It is well-known that transition-metal-doping induces dramatic changes in the structures and bonding of small boron clusters, as demonstrated by the newly observed perfect inverse sandwich D8h [La(η8-B8)La] and D9h [La(η9-B9)La]. Based on extensive global minimum searches and first-principles theory calculations, we predict herein the possibility of perfect endohedral trihedral metallo-borospherene D3h La@[La5&B30] (1, 3A’1) and its monoanion Cs La@[La5&B30] (2, 2A’) and dianion D3h La@[La5&B30]2- (3, 1A’1).

These La-doped boron clusters are composed of three inverse sandwich La(η8-B8)La on the waist and two inverse sandwich La(η9-B9)La on the top and bottom which share one apex La atom at the center and six periphery B2 units between neighboring η8-B8 and η9-B9 rings, with three octo-coordinate La atoms and two nona-coordinate La atoms as integrated parts of the cage surface.

Detailed adaptive natural density partitioning (AdNDP) and iso-chemical shielding surface (ICSS) analyses indicate that La@[La5&B30]0/-/2- (1/2/3) are spherically aromatic in nature. The one-dimensional nanowire La4B21 (4, Pm) constructed from D3h La@[La5&B30] (1) along the C3 axis of the system appears to be metallic. The IR and Raman spectra of La@[La5&B30] (1) and photoelectron spectroscopy of the slightly distorted Cs La@[La5&B30] (2) are theoretically simulated to facilitate their spectroscopic characterizations.

Towards the saving of global rainforests

Rainforests are the Earth’s largest terrestrial carbon sinks and are rapidly shrinking due to unprecedented human impact, especially tropical rainforests, which host ~50% of global biodiversity. Understanding what makes rainforests resilient on a long-term basis is key to preserving global rainforests and their ecological services.
Here, using estimates of rates-of-change (RoC) in fossil pollen records, an indicator for temporal compositional change (turnover) in vegetation, we show that accelerating trends in global rainforest changes (increasing RoC/turnover) during the last 12,000 years were mainly driven by intensive agricultural practices, and the highly diverse and productive tropical rainforests were the most impacted.
Management/conservation strategies aimed at the effective management of human impact will help promote rainforest health and diversity and increase resilience under projected climate change.

Recombinant Human Serine racemase

0.02mg(E-Coli) 320 EUR

Recombinant Human Serine racemase

0.1mg(E-Coli) 520 EUR

Recombinant Human Serine racemase

1mg(E-Coli) 1925 EUR

Recombinant Human Serine racemase

5x1mg(E-Coli) 8405 EUR

Recombinant Human Serine racemase

0.05mg 405 EUR

Recombinant Human Serine racemase

0.2mg 760 EUR

Recombinant Human Serine racemase

1mg 2175 EUR

Recombinant Human Serine racemase

5x1mg 8410 EUR

Recombinant Human Serine Racemase

0.001mg 240 EUR

Recombinant Human Serine Racemase

0.005mg 310 EUR

Fusogenic Viral Protein-Based Near-Infrared Active Nanocarriers for Biomedical

As a proof of concept, we bioengineered the vesicular stomatitis virus glycoprotein (VSV-G)-based near-infrared (NIR) active viral nanoconstructs (NAVNs) encapsulating indocyanine green dye (ICG) for NIR bioimaging.

NAVNs are spherical in size and have the intrinsic cellular-fusogenic properties of VSV-G. Further, the NIR imaging displaying higher fluorescence intensity in NAVNs treated cells suggests enhanced cellular uptake and delivery of ICG by NAVNs compared to the free form of ICG and for more information than visit joplink recombinant human to highlights. The overall study highlights the effectiveness of VSV-G-based VNPs as an efficient delivery system for NIR fluorescence imaging.

Phosphorylation of Trans-active response DNA binding protein-of 43 kDa promotes its cytoplasmic aggregation and modulates its function in tau mRNA stability and exon 10 alternative splicing

Trans-active response DNA-binding protein of 43 kDa (TDP-43) promotes tau mRNA instability and tau exon 10 inclusion. Aggregation of phosphorylated TDP-43 is associated with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). CK1ε phosphorylates TDP-43 at multiple sites, enhances its cytoplasmic aggregation and modu-lates its function in tau mRNA processing.

To determine roles of TDP-43 site-specific phos-phorylation in its localization, aggregation, and function in tau mRNA processing, TDP-43 was mutated to alanine or aspartic acid at Ser379, Ser403/404, or Ser409/410 to block or mimic phosphorylation. Site-specific phosphorylation of TDP-43 and its mutants by CK1ε was studied in vitro and in cultured cells. Cytoplasmic and nuclear TDP-43 and phospho-TDP-43 were analyzed by Western blots.

Aggregation of TDP-43 was assessed by immunostaining and level of RIPA-insoluble TDP-43. GFP tailed with tau 3′-UTR and mini-tau gene pCI/SI9-LI10 were used to study tau mRNA stability and alternative splicing of tau exon 10. We found that phospho-blocking mutations of TDP-43 at Ser379, Ser403/404, or Ser409/410 were not effectively phosphorylated by CK1ε.

Compared with TDP-43, higher level of phosphorylated TDP-43 in the cytoplasm was observed. Phospho-mimicking mutations at these sites enhanced cytoplasmic aggregation of TDP-43. GFP expression was not inhibited by phospho-blocking mutants of TDP-43, but tau exon 10 inclusion was further enhanced by phospho-blocking mutations at Ser379 and Ser403/404. Phosphorylation of TDP-43 at Ser379, Ser 403/404 or Ser409/410 primes its phosphorylation by CK1ε, promotes TDP-43 cytoplasmic aggregation and modulates its function in tau mRNA processing in site-specific manner.

Oncogenic mutations Q61L and Q61H confer active form-like structural features to the inactive state (state 1) conformation of H-Ras protein

GTP-bound forms of Ras proteins (Ras•GTP) assume two interconverting conformations, “inactive” state 1 and “active” state 2. Our previous study on the crystal structure of the state 1 conformation of H-Ras in complex with guanosine 5′-(β, γ-imido)triphosphate (GppNHp) indicated that state 1 is stabilized by intramolecular hydrogen-bonding interactions formed by Gln61. Since Ras are constitutively activated by substitution mutations of Gln61, here we determine crystal structures of the state 1 conformation of H-Ras•GppNHp carrying representative mutations Q61L and Q61H to observe the effect of the mutations.

The results show that these mutations alter the mode of hydrogen-bonding interactions of the residue 61 with Switch II residues and induce conformational destabilization of the neighboring regions. In particular, Q61L mutation results in acquirement of state 2-like structural features. Moreover, the mutations are likely to impair an intramolecular structural communication between Switch I and Switch II. Molecular dynamics simulations starting from these structures support the above observations. These findings may give a new insight into the molecular mechanism underlying the aberrant activation of the Gln61 mutants.

Effect of Active Coatings Containing Lippa citriodora Kunth. Essential Oil on Bacterial Diversity and Myofibrillar Proteins Degradation in Refrigerated Large Yellow Croaker

The research evaluated the effects of locust bean gum (LBG) and sodium alginate (SA) active coatings containing 0.15, 0.30 or 0.60% lemon verbena (Lippa citriodora Kunth.) essential oil (LVEO) on the bacterial diversity and myofibrillar proteins (MPs) of large yellow croaker during refrigerated storage at 4 °C for 18 days. Variability in the dominant bacterial community in different samples on the 0, 9th and 18th day was observed.

. Pseudomonas and Shewanella were the two major genera identified during refrigerated storage. At the beginning, the richness of Pseudomonas was about 37.31% and increased for control (CK) samples during refrigerated storage, however, the LVEO-treated samples increased sharply from day 0 to the 9th day and then decreased.

LBG-SA coatings containing LVEO treatments significantly delayed MPs oxidation by retarding the formation of free carbonyl compounds and maintaining higher sulfhydryl content, higher Ca2+-ATPase activity, better organized secondary (higher contents of α-helix and β-sheet) and tertiary structures during refrigerated storage.

The transmission electron microscope (TEM) images showed that the integrity of the sarcomere was damaged; the boundaries of the H-, A-, and I-bands, Z-disk, and M-line were fuzzy in the CK samples at the end of storage. However, the LVEO-treated samples were still regular in appearance with distinct dark A-bands, light I-bands, and Z-disk. In brief, LBG-SA active coatings containing LVEO treatments suggested a feasible method for protecting the MPs of large yellow croaker during refrigerated storage.

Ribosome-Inactivating Proteins of Bougainvillea glabra Uncovered Polymorphism and Active Site Divergence

Ribosome-inactivating proteins (RIPs) are toxic proteins that can inhibit protein synthesis. RIPs purified from Bougainvillea have low nonspecific toxicity, showing promise for processing applications in the agricultural and medical fields. However, systematic research on the polymorphism of Bougainvillea RIPs is lacking, and it is worth exploring whether different isoforms differ in their active characteristics. The transcriptional and translational expression of type I RIPs in Bougainvillea glabra leaves was investigated in this study. Seven RIPs exhibited seasonal variation at both the mRNA and protein levels.

The isoforms BI4 and BI6 showed the highest transcriptional expression in both the summer and autumn samples. Interestingly, BI6 was not detected in the protein level in any of the samples. However, the bioinformatics analysis showed that RIPs derived from the same species were gathered in a different cluster, and that the active sites changed among the isoforms during evolution.

The significant discrepancy in Bougainvillea RIPs mainly locates at both termini of the amino acid sequence, particularly at the C terminus. Post-translational modifications may also exist in Bougainvillea RIPs. It is concluded that the reason for the polymorphism of Bougainvillea RIPs may be that these proteins are encoded by multiple genes due to genetic processes such as gene duplication and mutation. According to the results of sequence analysis, the possible functional differences of B. glabra RIP isoforms are discussed with regard to the observed discrepancy in both active sites and structures.

 

Recombinant Human C5AR1

0.05mg 345 EUR

Recombinant Human C5AR1

0.2mg 635 EUR

Recombinant Human C5AR1

1mg 1800 EUR

Recombinant Human C5AR1

5x1mg 6955 EUR

C5AR1 Recombinant Protein (Human)

100 ug Ask for price

Recombinant Human C5AR1, His-tagged

25ug 255.2 EUR

Recombinant Human C5AR1 protein, C-His Tag(VLPs)

20µg 720 EUR

Recombinant Human C5a anaphylatoxin chemotactic receptor (C5AR1)

7851 mg Ask for price

Recombinant Human C5a anaphylatoxin chemotactic receptor (C5AR1)

100ug 3430.4 EUR

Recombinant Human C5a anaphylatoxin chemotactic receptor (C5AR1)

20ug 2101.8 EUR

Argentina’s Local Crop Biotechnology Developments: Why Have They Not Reached the Market Yet?

Argentina's Local Crop Biotechnology Developments: Why Have They Not Reached the Market Yet?

Plant biotechnology in Argentina started at the end of the 1980s, leading to the development of numerous research groups in public institutions and, a decade later, to some local private initiatives. The numerous scientific and technological capacities existing in the country allowed the early constitution in 1991 of a sound genetically modified organisms biosafety regulatory system.

The first commercial approvals began in 1996, and to date, 59 events have obtained permits to be placed on the market, however, only two have been developed locally by public-private partnerships. The transgenic events developed at public institutions pursue different objectives in diverse crops.

However, once these events have been developed in laboratories, it is difficult to move toward a possible commercial approval. In this work, we analyze several reasons that could explain why local developments have not reached approvals for commercialization, highlighting aspects related to the lack of strategic vision in the institutions to focus resources on projects to develop biotechnological products.

Although progress has been made in generating regulatory rules adapted to research institutes (such as the regulations for biosafety greenhouses and ways of presenting applications), researchers still do not conceive regulatory science as a discipline. They generally prefer not to be involved in the design of regulatory field trials or regulatory issues related to the evaluation of events. In that sense, some of the aspects considered a regulatory affairs platform for the public scientific system and the reinforcement of laboratories that perform tests required under the Argentine regulation.

Argentina's Local Crop Biotechnology Developments: Why Have They Not Reached the Market Yet?
Argentina’s Local Crop Biotechnology Developments: Why Have They Not Reached the Market Yet?

Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology.

Forty-three years after it was founded, with billions of dollars invested, the global biotech industry is still not positioned as a mature low-risk sector for the international investor com-munity.

Despite the clear commercial success of a number of leading companies and overall growth of the industry’s rev-enues, most biotech companies are not profi table and many fail to overcome the formidable barrier constituted by the high cost of the sector’s research and development. However, over the last four years, visible signs of change have appeared, which could be harbingers of an approaching turning point in this trend.

This article analyzes the historic background of the biotech in-dustry’s business models and corporate structures, as well as their impact on the industry’s fi nancial framework. It examines recent changes implemented by the sector’s main actors-in-cluding young startups, venture capital funds and big pharma companies-to mitigate fi nancial risk associated with develop-ment of new biotechnology products.

EGTA

ED0077 25g
EUR 87.14

EGTA

E440150 100g
EUR 119
Description: 67-42-5

EGTA

B7195-1000 1 g
EUR 39
Description: Calcium chelator

EGTA

A2506-100G 100G
EUR 138.6
Description: Ultra Pure

EGTA

A2506-10G 10G
EUR 26.4
Description: Ultra Pure

EGTA

A2506-25G 25G
EUR 46.2
Description: Ultra Pure

EGTA

GE7249 10g
EUR 108.65

EGTA

GE7249-10 10
EUR 22.1

EGTA

GE7249-100 100
EUR 118.7

EGTA

GE7249-100G 100 g
EUR 180

EGTA

GE7249-10G 10 g
EUR 62.4

EGTA

GE7249-25 25
EUR 39.4

EGTA

GE7249-25G 25 g
EUR 84

EGTA

GE7249-50 50
EUR 67.2

EGTA

GE7249-50G 50 g
EUR 117.6

EGTA

T4585-10mg 10mg Ask for price
Description: EGTA

EGTA

T4585-1g 1g Ask for price
Description: EGTA

EGTA

T4585-1mg 1mg Ask for price
Description: EGTA

EGTA

T4585-50mg 50mg Ask for price
Description: EGTA

EGTA

T4585-5mg 5mg Ask for price
Description: EGTA

EGTA

abx082266-100l 100 µl
EUR 125

EGTA

abx082266-1ml 1 ml Ask for price

EGTA

abx082266-200l 200 µl Ask for price

EGTA

abx082565-100l 100 µl
EUR 125

EGTA

abx082565-1ml 1 ml Ask for price

EGTA

abx082565-200l 200 µl Ask for price

EGTA

MBS635349-100g 100g
EUR 500

EGTA

MBS635349-10g 10g
EUR 185

EGTA

MBS635349-250g 250g
EUR 860

EGTA

MBS635349-25g 25g
EUR 240

EGTA

MBS635349-50g 50g
EUR 345

EGTA 99%

E00340 10G
EUR 228.91

EGTA, 99%

GE9981 10g
EUR 275.2

EGTA, 99%

GE9981-10 10
EUR 30.9

EGTA, 99%

GE9981-100 100
EUR 150.4

EGTA, 99%

GE9981-100G 100 g
EUR 217.2

EGTA, 99%

GE9981-10G 10 g
EUR 73.2

EGTA, 99%

GE9981-25 25
EUR 53.8

EGTA, 99%

GE9981-250 250
EUR 300.5

EGTA, 99%

GE9981-250G 250 g
EUR 399.6

EGTA, 99%

GE9981-25G 25 g
EUR 100.8

EGTA, 99%

GE9981-50 50
EUR 89.3

EGTA, 99%

GE9981-50G 50 g
EUR 144

EGTA, AM

MBS8579925-10mg 10mg
EUR 570

EGTA, AM

MBS8579925-5x10mg 5x10mg
EUR 2495

EGTA-AM

HY-D0973 5mg
EUR 704.4

EGTA-AM

T13673-10mg 10mg Ask for price
Description: EGTA-AM

EGTA-AM

T13673-1g 1g Ask for price
Description: EGTA-AM

EGTA-AM

T13673-1mg 1mg Ask for price
Description: EGTA-AM

EGTA-AM

T13673-50mg 50mg Ask for price
Description: EGTA-AM

EGTA-AM

T13673-5mg 5mg Ask for price
Description: EGTA-AM

EGTA-AM

MBS5754297-25mg 25mg
EUR 1230

EGTA-AM

MBS5754297-5x25mg 5x25mg
EUR 5395

EGTA (2x) Buffer

MBS565489-1mL 1mL
EUR 150

EGTA (2x) Buffer

MBS565489-5x1mL 5x1mL
EUR 525

EGTA tetrasodium salt

MBS8579926-1g 1g
EUR 280

EGTA tetrasodium salt

MBS8579926-5x1g 5x1g
EUR 1195

EGTA 100mM, pH 7.4, Sterile

40120129-1 50 mL
EUR 38.95

EGTA 100mM, pH 7.4, Sterile

40120129-2 100 mL
EUR 49.81

EGTA 100mM, pH 7.4, Sterile

40120129-3 250 mL
EUR 96.89

EGTA, Hi-LR™

GRM1530-10G 1 unit
EUR 33.64
Description: EGTA, Hi-LR™

EGTA, Hi-LR™

GRM1530-25G 1 unit
EUR 73.94
Description: EGTA, Hi-LR™

RIPA Buffer with EGTA

42020012-1 250 mL
EUR 39.56

RIPA Buffer with EGTA

42020012-2 500 mL
EUR 74.96

EGTA, Molecular Biology Grade

40500028-2 50 g
EUR 106.43

EGTA, Molecular Biology Grade

40500028-3 100 g
EUR 177.58

EGTA, Molecular Biology Grade

40500028-4 500 g
EUR 603.19

EGTA, Molecular Biology Grade

40500028-5 1 kg
EUR 912.98

EGTA, Molecular Biology Grade

40500028-6 2 kg
EUR 1687.94

EGTA 1M, pH 7.4, Sterile

40120127-1 50 mL
EUR 45.36

EGTA 1M, pH 7.4, Sterile

40120127-2 100 mL
EUR 66.59

EGTA 1M, pH 7.4, Sterile

40120127-3 500 mL
EUR 336.81

EGTA 1M, pH 8.0, Sterile

40120128-1 50 mL
EUR 45.36

EGTA 1M, pH 8.0, Sterile

40120128-2 100 mL
EUR 66.59

EGTA 1M, pH 8.0, Sterile

40120128-3 500 mL
EUR 336.81

EGTA 0.5M, pH 7.4, Sterile

40120370-1 50 mL
EUR 37.64

EGTA 0.5M, pH 7.4, Sterile

40120370-2 100 mL
EUR 66.11

EGTA 0.5M, pH 7.4, Sterile

40120370-3 250 mL
EUR 112.92

EGTA 0.5M, pH 7.4, Sterile

40120370-4 1 L
EUR 375.43

EGTA 0.5M, pH 8.0, Sterile

40520008-1 50 mL
EUR 38.95

EGTA 0.5M, pH 8.0, Sterile

40520008-2 100 mL
EUR 66.11

EGTA 0.5M, pH 8.0, Sterile

40520008-3 250 mL
EUR 112.92

EGTA 0.5M, pH 8.0, Sterile

40520008-4 1 L
EUR 375.43

MOPS Buffer with EGTA 10X

40120884-1 100 mL
EUR 33.86

MOPS Buffer with EGTA 10X

40120884-2 500 mL
EUR 85.98

RIPA Buffer with EDTA & EGTA

42020008-1 250 mL
EUR 39.56

RIPA Buffer with EDTA & EGTA

42020008-2 500 mL
EUR 65.37

EGTA AM *CAS 99590-86-0*

21005-10mg 10 mg
EUR 166
Description: EGTA AM is cell-permeable version of EGTA (ethylene glycol tetraacetic acid), a cell-permeable calcium chelator.

EGTA AM *10 mM DMSO solution*

21006-1mL 1 mL
EUR 166
Description: EGTA AM is cell-permeable version of EGTA (ethylene glycol tetraacetic acid), a cell-permeable calcium chelator.

MOPS Buffer with EGTA 10X, Sterile

40120885-1 100 mL
EUR 37.73

MOPS Buffer with EGTA 10X, Sterile

40120885-2 500 mL
EUR 111.42

EGTA tetrasodium salt *CAS 13368-13-3*

21007-1g 1 g
EUR 86
Description: EGTA (1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) is a water-soluble and cell-impermeable calcium chelator.

EGTA tetrasodium salt *10 mM aqueous solution*

21008-10mL 10 mL
EUR 86
Description: EGTA (1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) is a water-soluble and cell-impermeable calcium chelator.

Mg2 + -EGTA-ATPase test cassette (colorimetric method)

SH0266-1 50T/25Sample
EUR 220

Mg2 + -EGTA-ATPase test cassette (colorimetric method)

SH0266-2 100T/50Sample
EUR 280

Paraformaldehyde (4%) Fixative in PBS with Mg and EGTA

30450001-1 250 mL
EUR 29.99

Paraformaldehyde (4%) Fixative in PBS with Mg and EGTA

30450001-2 500 mL
EUR 53.99

2xRIPA Buffer IIII with EDTA and EGTA (pH 7.4) 2xconcentrate

RB4477 500ml
EUR 86.1

Ethylene Glycol-O-O-bis-(2-Aminoethyl) N,N,N,N-Tetraacetic Acid (EGTA) extrapure, 98%

62858 10 Gms
EUR 21.38
Description: Part B

Egtazic acid

463846 50.0mg Ask for price

EGT1442

MBS131659-100mg 100mg
EUR 1065

EGT1442

MBS131659-500mg 500mg
EUR 2775

EGT1442

MBS386480-10mg 10mg
EUR 285

EGT1442

MBS386480-25mg 25mg
EUR 510

EGT1442

MBS386480-5mg 5mg
EUR 220

EGT1442

MBS386480-5x25mg 5x25mg
EUR 2280

EGT1442

MBS5752420-10mg 10mg
EUR 260

EGT1442

MBS5752420-25mg 25mg
EUR 435

EGT1442

MBS5752420-2mg 2mg
EUR 175

EGT1442

MBS5752420-50mg 50mg
EUR 610

EGT1442

MBS5752420-5mg 5mg
EUR 210

Bexgliflozin (EGT1442)

B1929-1 each
EUR 170.4

Bexgliflozin (EGT1442)

B1929-5 each
EUR 496.8

Bexagliflozin?EGT1442

MBS131294-100mg 100mg
EUR 1495

Recombinant Saccharomyces cerevisiae Protein EGT2 (EGT2) , partial

MBS1076136-INQUIRE INQUIRE Ask for price

EGTT-Scavenger for GSH/GSSG Assays (EGTT-100)

EGTT-SCVG 100
EUR 89

Recombinant Mycobacterium smegmatis Amidohydrolase EgtC (egtC)

MBS1110091-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1120

Recombinant Mycobacterium smegmatis Amidohydrolase EgtC (egtC)

MBS1110091-002mgEColi 0.02mg(E-Coli)
EUR 735

Recombinant Mycobacterium smegmatis Amidohydrolase EgtC (egtC)

MBS1110091-002mgYeast 0.02mg(Yeast)
EUR 900

Recombinant Mycobacterium smegmatis Amidohydrolase EgtC (egtC)

MBS1110091-01mgEColi 0.1mg(E-Coli)
EUR 880

Recombinant Mycobacterium smegmatis Amidohydrolase EgtC (egtC)

MBS1110091-01mgYeast 0.1mg(Yeast)
EUR 1050

Recombinant Mycobacterium tuberculosis Amidohydrolase EgtC (egtC)

MBS1046064-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1115

Recombinant Mycobacterium tuberculosis Amidohydrolase EgtC (egtC)

MBS1046064-002mgEColi 0.02mg(E-Coli)
EUR 740

Recombinant Mycobacterium tuberculosis Amidohydrolase EgtC (egtC)

MBS1046064-002mgYeast 0.02mg(Yeast)
EUR 905

Recombinant Mycobacterium tuberculosis Amidohydrolase EgtC (egtC)

MBS1046064-01mgEColi 0.1mg(E-Coli)
EUR 890

Recombinant Mycobacterium tuberculosis Amidohydrolase EgtC (egtC)

MBS1046064-01mgYeast 0.1mg(Yeast)
EUR 1060

Rabbit anti-Saccharomyces cerevisiae (strain ATCC 204508/S288c)(Baker's yeast) EGT2 Polyclonal Antibody

MBS7155837-INQUIRE INQUIRE Ask for price

Rabbit anti-Schizosaccharomyces pombe (strain 972/ATCC 24843)(Fission yeast) EGT1 Polyclonal Antibody

MBS7183038-INQUIRE INQUIRE Ask for price

Rabbit anti-Schizosaccharomyces pombe (strain 972/ATCC 24843)(Fission yeast) EGT2 Polyclonal Antibody

MBS7183415-INQUIRE INQUIRE Ask for price

Recombinant Mycobacterium smegmatis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1184513-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1245

Recombinant Mycobacterium smegmatis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1184513-002mgEColi 0.02mg(E-Coli)
EUR 910

Recombinant Mycobacterium smegmatis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1184513-002mgYeast 0.02mg(Yeast)
EUR 1035

Recombinant Mycobacterium smegmatis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1184513-01mgEColi 0.1mg(E-Coli)
EUR 1095

Recombinant Mycobacterium smegmatis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1184513-01mgYeast 0.1mg(Yeast)
EUR 1180

Recombinant Mycobacterium smegmatis Histidine-specific methyltransferase EgtD (egtD)

MBS1143325-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1200

Recombinant Mycobacterium smegmatis Histidine-specific methyltransferase EgtD (egtD)

MBS1143325-002mgEColi 0.02mg(E-Coli)
EUR 850

Recombinant Mycobacterium smegmatis Histidine-specific methyltransferase EgtD (egtD)

MBS1143325-002mgYeast 0.02mg(Yeast)
EUR 990

Recombinant Mycobacterium smegmatis Histidine-specific methyltransferase EgtD (egtD)

MBS1143325-01mgEColi 0.1mg(E-Coli)
EUR 1020

Recombinant Mycobacterium smegmatis Histidine-specific methyltransferase EgtD (egtD)

MBS1143325-01mgYeast 0.1mg(Yeast)
EUR 1125

Recombinant Mycobacterium tuberculosis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1173767-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1265

Recombinant Mycobacterium tuberculosis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1173767-002mgEColi 0.02mg(E-Coli)
EUR 935

Recombinant Mycobacterium tuberculosis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1173767-002mgYeast 0.02mg(Yeast)
EUR 1055

Recombinant Mycobacterium tuberculosis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1173767-01mgEColi 0.1mg(E-Coli)
EUR 1125

Recombinant Mycobacterium tuberculosis Pyridoxal-phosphate-dependent protein EgtE (egtE)

MBS1173767-01mgYeast 0.1mg(Yeast)
EUR 1200

Recombinant Mycobacterium tuberculosis Histidine-specific methyltransferase EgtD (egtD)

MBS1224849-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1200

Recombinant Mycobacterium tuberculosis Histidine-specific methyltransferase EgtD (egtD)

MBS1224849-002mgEColi 0.02mg(E-Coli)
EUR 850

Recombinant Mycobacterium tuberculosis Histidine-specific methyltransferase EgtD (egtD)

MBS1224849-002mgYeast 0.02mg(Yeast)
EUR 990

Recombinant Mycobacterium tuberculosis Histidine-specific methyltransferase EgtD (egtD)

MBS1224849-01mgEColi 0.1mg(E-Coli)
EUR 1020

Recombinant Mycobacterium tuberculosis Histidine-specific methyltransferase EgtD (egtD)

MBS1224849-01mgYeast 0.1mg(Yeast)
EUR 1125

Recombinant Mycobacterium Smegmatis egtD Protein (aa 1-321)

VAng-Yyj4655-1mgEcoli 1 mg (E. coli)
EUR 5091.6
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Histidine-specific methyltransferase EgtD (egtD), recombinant protein.

Recombinant Mycobacterium Smegmatis egtD Protein (aa 1-321)

VAng-Yyj4655-500gEcoli 500 µg (E. coli)
EUR 3606
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Histidine-specific methyltransferase EgtD (egtD), recombinant protein.

Recombinant Mycobacterium Smegmatis egtD Protein (aa 1-321)

VAng-Yyj4655-50gEcoli 50 µg (E. coli)
EUR 2469.6
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Histidine-specific methyltransferase EgtD (egtD), recombinant protein.

Recombinant Mycobacterium Smegmatis egtB Protein (aa 1-428)

VAng-Yyj4891-1mgEcoli 1 mg (E. coli)
EUR 5900.4
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Iron (II)-dependent oxidoreductase EgtB, recombinant protein.

Recombinant Mycobacterium Smegmatis egtB Protein (aa 1-428)

VAng-Yyj4891-500gEcoli 500 µg (E. coli)
EUR 4167.6
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Iron (II)-dependent oxidoreductase EgtB, recombinant protein.

Recombinant Mycobacterium Smegmatis egtB Protein (aa 1-428)

VAng-Yyj4891-50gEcoli 50 µg (E. coli)
EUR 2848.8
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Iron (II)-dependent oxidoreductase EgtB, recombinant protein.

Recombinant Mycobacterium Smegmatis egtC Protein (aa 1-227)

VAng-Yyj4892-1mgEcoli 1 mg (E. coli)
EUR 4365.6
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Amidohydrolase EgtC (egtC), recombinant protein.

Recombinant Mycobacterium Smegmatis egtC Protein (aa 1-227)

VAng-Yyj4892-500gEcoli 500 µg (E. coli)
EUR 3129.6
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Amidohydrolase EgtC (egtC), recombinant protein.

Recombinant Mycobacterium Smegmatis egtC Protein (aa 1-227)

VAng-Yyj4892-50gEcoli 50 µg (E. coli)
EUR 2122.8
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Amidohydrolase EgtC (egtC), recombinant protein.

Recombinant Mycobacterium Smegmatis egtE Protein (aa 1-371)

VAng-Yyj4893-1mgEcoli 1 mg (E. coli)
EUR 5470.8
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Pyridoxal-phosphate-dependent protein EgtE (egtE), recombinant protein.

Recombinant Mycobacterium Smegmatis egtE Protein (aa 1-371)

VAng-Yyj4893-500gEcoli 500 µg (E. coli)
EUR 3870
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Pyridoxal-phosphate-dependent protein EgtE (egtE), recombinant protein.

Recombinant Mycobacterium Smegmatis egtE Protein (aa 1-371)

VAng-Yyj4893-50gEcoli 50 µg (E. coli)
EUR 2650.8
Description: Mycobacterium Smegmatis (strain ATCC 700084 / mc(2)155) Pyridoxal-phosphate-dependent protein EgtE (egtE), recombinant protein.

Recombinant Echinococcus Granulosus EgTrpA Protein (aa 1-278)

VAng-Ly4003-1mgEcoli 1 mg (E. coli)
EUR 4761.6
Description: Echinococcus Granulosus tropomyosin A (EgTrpA), recombination protein.

Recombinant Echinococcus Granulosus EgTrpA Protein (aa 1-278)

VAng-Ly4003-500gEcoli 500 µg (E. coli)
EUR 3376.8
Description: Echinococcus Granulosus tropomyosin A (EgTrpA), recombination protein.

Recombinant Echinococcus Granulosus EgTrpA Protein (aa 1-278)

VAng-Ly4003-50gEcoli 50 µg (E. coli)
EUR 2304
Description: Echinococcus Granulosus tropomyosin A (EgTrpA), recombination protein.

Recombinant Mycobacterium smegmatis Iron (II)-dependent oxidoreductase EgtB

MBS1135713-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1300

Recombinant Mycobacterium smegmatis Iron (II)-dependent oxidoreductase EgtB

MBS1135713-002mgEColi 0.02mg(E-Coli)
EUR 980

Recombinant Mycobacterium smegmatis Iron (II)-dependent oxidoreductase EgtB

MBS1135713-002mgYeast 0.02mg(Yeast)
EUR 1090

Recombinant Mycobacterium smegmatis Iron (II)-dependent oxidoreductase EgtB

MBS1135713-01mgEColi 0.1mg(E-Coli)
EUR 1145

Recombinant Mycobacterium smegmatis Iron (II)-dependent oxidoreductase EgtB

MBS1135713-01mgYeast 0.1mg(Yeast)
EUR 1240

Finally, it discusses the challenges and opportunities that these tendencies entail for Cuban biotechnology development and proposes adoption of business policies more tolerant of the fi nancial risk inherent in this sector, as a condition for at-tracting venture capital. KEYWORDS Biotechnology, fund raising, risk management, entrepreneurship, Cuba.